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Antigen-specific antibody Fc glycosylation enhances
humoral immunity via the recruitment of complement
Giuseppe Lofano1*, Matthew J. Gorman1*, Ashraf S. Yousif1,2*, Wen-Han Yu1,3*, Julie M. Fox4,
Anne-Sophie Dugast1, Margaret E. Ackerman5, Todd J. Suscovich1, Joshua Weiner5,
Dan Barouch1,6, Hendrik Streeck7, Susan Little8, Davey Smith8,9, Douglas Richman8,9,
Douglas Lauffenburger3, Bruce D. Walker1,10,11, Michael S. Diamond4, Galit Alter1†

INTRODUCTION

The development of a protective vaccine against HIV will likely require the induction of highly cross-reactive broadly neutralizing antibodies (bNAbs). Although current vaccination regimens can readily
induce Abs capable of neutralizing autologous viruses (1, 2), these immunization strategies have generated only weakly cross-neutralizing
(heterologous) Abs (3, 4). Although vaccination has failed to induce
Abs with appreciable neutralization breadth, 5 to 30% of infected
individuals naturally develop bNAbs, albeit after several years of infection (5, 6) and one step behind the autologous virus (7). Thus, elucidating the immunological processes that allow some individuals to
overcome the immunologic barrier to developing neutralizing breadth
may provide critical insights for the development of a vaccine capable
of inducing bNAbs.
Although our understanding of the molecular and structural
features of Abs that allow for broad neutralization has increased
markedly over the past decade (8, 9), the underlying immunological
pathways that lead to these unusual features have yet to be fully elucidated. Nearly all bNAbs develop after extensive somatic hyper1
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mutation and often contain mutated framework regions (9, 10),
features that are indicative of the prolonged affinity maturation.
Previous studies have linked high viral loads, low CD4 T cell counts,
and immune activation in the evolution of bNAbs (11–14). In the
setting of low levels of viremia and high CD4 counts, bNAb activity
still evolves, but only in the setting of a unique plasma type I interferon and germinal center (GC)–centric cytokine signature, pointing
to the need for persistent GC activity (15). Yet, how these individ
uals maintain GC activity, particularly in the setting of low antigenic
loads, is unclear.
Antigen delivery to the lymph node, and specifically to follicular
dendritic cells (FDCs), plays a key role in both initiating and sustaining the GC reaction (16). Specifically, antigen may be delivered to
the lymph node via both “naked” antigen diffusion from the lymph
or active antigen delivery via the delivery of antigen in the form of
immune complexes (ICs) by noncognate B cells or local macrophages
(17–20). Although HIV antigens likely arrive in the GC in the absence of Ab opsonization in acute HIV infection, high titers of HIV-
specific Abs are induced over the course of infection that contribute to
IC formation (21, 22), antigen capture and delivery, and seeding of
antigens in the GC (23). However, whether differences in IC quality
could contribute to GC generation and persistence, affinity maturation,
and the evolution of neutralization breadth is unknown.
IC activity is modulated by both the Fab and Fc domains of the
Ab. The Fab drives antigen specificity, whereas the Fc region determines which innate immune receptors, including Fc receptors (FcRs)
and complement receptors (CRs), ICs can bind. Depending on the
FcRs and CRs engaged by an IC, antigens can be rapidly destroyed
or transported to the GC for antigen presentation (18, 19, 24–27).
Hence, modifications to the Fc domain, including changes in Ab
isotype/subclass and glycosylation (28–31), may have a profound impact on IC delivery via improved IC affinity for particular FcRs/CRs.
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HIV-specific broadly neutralizing antibodies (bNAbs) confer protection after passive immunization, but the immunological mechanisms that drive their development are poorly understood. Structural features of bNAbs indicate
that they originate from extensive germinal center (GC) selection, which relies on persistent GC activity. However,
why a fraction of infected individuals are able to successfully drive more effective affinity maturation is unclear.
Delivery of antigens in the form of antibody-immune complexes (ICs), which bind to complement receptors (CRs)
or Fc receptors (FcRs) on follicular dendritic cells, represents an effective mechanism for antigen delivery to the
GC. We sought to define whether IC-FcR or CR interactions differ among individuals who develop bNAb responses
to HIV. Enhanced Fc effector functions and FcR/CR interactions, via altered Fc glycosylation profiles, were observed
among individuals with neutralizing antibody responses to HIV compared with those without neutralizing antibody activity. Moreover, both polyclonal neutralizer ICs and monoclonal IC mimics of neutralizer antibodies induced higher antibody titers, higher-avidity antibodies, and expanded GC B cell reactions after immunization of
mice via accelerated antigen deposition within B cell follicles in a complement-dependent manner. Thus, these
data point to a direct role for altered Fc profile/complement interactions in shaping the maturation of the humoral
immune response, providing insights into how GC activity may be enhanced to drive affinity maturation in next-
generation vaccine approaches.
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RESULTS

Selective Fc functional profile differences
exist among neutralizers
Given previous associations of the evolution of neutralizing Ab
breadth in the setting of high immune activation, low CD4 counts, and
high viral loads (12, 14), we aimed to dissect the potential involvement of changes in IC biology in a group of spontaneous controllers
of HIV (≤2000 copies/ml), a fraction of whom developed bNAb responses, despite the absence of high levels of plasma antigenemia (15).
Despite lower viremia, previous studies demonstrated that equal numbers of controllers evolve neutralization breadth (15) compared with
normal progressors (12, 14). Seventy-one participants were included
in this study, with neutralization breadth ranging from 9 to 100%
coverage of a panel of 11 tier 2/3 viruses (neutralizers) that were compared with a matched group of 60 participants with no evidence of
neutralizing Ab breadth (0% neutralizing activity across 11 tier 2 and
tier 3 viruses; non-neutralizers). The two groups were matched for
duration of infection, viral loads, and CD4 counts.
No differences in the ability of Abs to recruit natural killer (NK)
cells to kill HIV envelope–coated target cells in an Ab-dependent
cellular cytotoxicity (ADCC) assay were observed between the neutralizers and non-neutralizers (Fig. 1A). In contrast, significant differences were observed in the capacity of neutralizer Abs to direct
Ab-dependent cellular phagocytosis (ADCP) and Ab-dependent
complement deposition (ADCD) (Fig. 1, B and C). Given the use of
different FcRs in driving distinct innate functions, these data suggested that neutralizer Abs were selectively skewed to drive enhanced
phagocytic and complement-depositing activity, but not NK cell
cytotoxicity.
To further dissect the specific FcRs that were selectively recruited
by neutralizer Abs, we used a multiparametric Luminex assay to
measure differences in IC binding to a spectrum of Fc receptors
(FcRs) and complement proteins. With a panel of HIV envelope–
conjugated Luminex beads, ICs were formed, and binding to the ICs
Lofano et al., Sci. Immunol. 3, eaat7796 (2018)
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Fig. 1. Unique Fc functional profiling of HIV-specific Abs from neutralizers.
(A to C) Serum Abs from neutralizers (N; purple) and non-neutralizers (NN; yellow) were
evaluated for their ability to promote NK-dependent ADCC against gp120-pulsed
CD4+ T cells (A), monocyte-directed phagocytosis of gp120-functionalized fluorescent
beads (B), or complement deposition (C3b) on the surface of gp120-pulsed CD4+
target cells (C). All assays were performed in duplicate or triplicate across all 131 individuals. An unpaired t test was used for statistical analysis. *P < 0.05 and **P < 0.01.
The horizontal bars in all panels indicate mean.

by FcRs and complement was measured. A subset of the original
cohort, composed of 38 individuals broadly covering a range of neutralization breadths (0 to 100%) (Fig. 2A and table S1), for whom
sufficient plasma was available, was included in this analysis. The
individuals included 26 participants who neutralized between 9 and
100% of the 11 tested tier 2/3 viruses and 12 participants with no evidence of neutralizing Ab breadth (Fig. 2A and table S1). In addition,
viral loads, CD4 counts, days after diagnosis, and distribution of
ADCD, ADCC, and ADCP responses were similar between the
groups. Marked differences were observed among the neutralizer
and non-neutralizer Abs in their ability to bind to C1q and FcRs
(Fig. 2B). Specifically, a higher proportion of neutralizers exhibited
enhanced gp41-specific FcR binding and enhanced gp120 and gp140
binding to FcRIIIA and FcRIIIB, and a select set of neutralizers
also showed stronger binding to C1q (Fig. 2B). Univariate analysis
highlighted the overall elevated levels of FcR/C1q binding Abs among
neutralizers (Fig. 2C). Moreover, positive associations between breadth
and FcR/C1q binding were observed across all HIV-specific Ab responses; however, only gp140- and gp41-specific Ab binding to FcRIIB
and C1q was statistically significant (Fig. 2D). These data suggest an
overall enhanced FcRs and C1q binding profile in Abs from neutralizers compared with non-neutralizers, consistent with enhanced
ADCD and ADCP (Fig. 1). Furthermore, previous longitudinal analysis pointed to significantly enhanced Fc function and receptor binding
among individuals who went on to generate neutralizing responses
before the evolution of the neutralizing Abs (34). Likewise, analysis
of plasma samples from a separate cohort of acutely infected individuals, half of whom went on to generate neutralizing Abs, pointed
to selectively elevated gp120-specific FcRIIA binding preceding the
evolution of bNAbs after 2 years of infection (Fig. 2E) (7). Given the
importance of both FcR and C1q in the delivery of IC cargo to the GC
(17, 35, 36), these data point to unique IC profiles among neutralizers
with a higher intrinsic capacity to interact with Fc-binding proteins
involved in antigen delivery to the GC, thereby potentially contributing to persistent GC activity and enhanced affinity maturation.
HIV-specific Abs from neutralizers promote GC reactions
To test the hypothesis that differences in Fc profiles generated in
neutralizers and non-neutralizers were responsible for differences in
2 of 12
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Along these lines, influenza-specific Fc Ab glycosylation after vaccination is associated with enhanced affinity maturation of the influenza-
specific response (32), highlighting the potential influence of the
Fc domain changes after vaccination on the antiviral activity of the
vaccine-induced immune response.
We speculated that qualitative changes in the Fc domain track with
the development of bNAbs during HIV infection and point to the
mechanism by which the Fc domain of the Ab may be leveraged to
drive the evolution of highly affinity-matured bNab responses. Using
“systems serology” (33), we observed significant differences in the
Fc profiles of HIV-specific Abs in individuals who developed neutralizing breadth (neutralizers) compared with those who did not
(non-neutralizers). Moreover, immunization with ICs generated with
polyclonal Abs from neutralizers induced higher HIV-specific Ab responses after vaccination. This biological activity was linked to particular Ab glycosylation profiles, which, when replicated with monoclonal
IC immunization, resulted in enhanced IC capture by noncognate B cells,
accelerated IC deposition within B cell follicles, and elevated Ab titers
and avidity Ab production in a complement-dependent manner. Collectively, these data point to Fc glycosylation as a direct modulator of
B cell immunity and suggest an approach by which next-generation
vaccines can exploit both ends of the Ab to drive enhanced B cell affinity maturation that may be required against highly mutable targets.
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Fig. 2. Enhanced, but selective, FcR and complement binding by HIV-specific Abs in neutralizers. (A) The rainbow heat map shows the breadth of neutralization and
sample ID number across the 26 neutralizers and 12 non-neutralizers that were profiled more deeply in this and subsequent figures. (B) The larger heat map illustrates
the binding capacity (MFI) of gp140-, gp120-, gp41-, and p24-specific serum Abs to FcRIIA, FcRIIB, FcRIIIA, FcRIIIB, and C1q protein. Row 19 represents the breadth of
neutralization. Each additional row represents the binding level for a single antigen specificity to a single FcR/C1q. Each column represents one individual (sample ID
number is below the heat map), either a neutralizer (red box) or a non-neutralizer (blue box). Data were normalized across rows. The scale bar represents the Z-normalized
scores. (C) The dot plot represents the representative univariate binding of gp120-specific Abs from each group to FcRIIA, FcRIIB, FcRIIIA, FcRIIIB, and C1q. (D) The heat
map strip highlights the correlation between gp140-, gp120-, gp41-, and p24-specific Ab binding to each FcR/C1q and the breadth of neutralization across all neutralizers and
non-neutralizers. (E) The hybrid dot/bar plot shows the evolution of gp120-specific FcRIIA binding Abs in the first year after infection in a group of acutely infected HIV
participants, half of which went on to develop bNAbs (purple) or not (yellow). Each dot represents one individual, with neutralizers (N) in violet and non-neutralizers (NN) in
yellow. A Mann-Whitney test was used for statistical analysis to compare groups in (C). An ANOVA, with a post hoc Tukey’s test, was used to compare between groups across
time points in (E). A Spearman correlation with a post hoc Bonferroni correction was used to examine the relationship between Fc profiles and breadth of neutralization
(D). *P < 0.05 and **P < 0.01. The horizontal bars in all panels indicate mean. Error bars represent standard error of mean (SEM) in (C) and standard deviation (SD) in (E).

GC reactions and affinity maturation, we generated ICs from neutralizers and non-neutralizers. Ab pools were generated from four
neutralizers and four non-neutralizers, matched for gp120-specific
Ab titers and avidity (fig. S1A). Specifically, recombinant HIV gp120
proteins were complexed with polyclonal Abs from neutralizer and non-
neutralizer pools at Ab concentrations aimed at achieving equivalent
IC occupancy (fig. S1, B and C). All complexes were co-delivered to
mice with alum as a baseline comparator to standard immunization.
Thus, equivalent amounts of alum-adjuvanted ICs, alum-adjuvanted
gp120, or alum alone were administered. Mice received two immunizations, 3 weeks apart, and 10 days after the last immunization,
gp120-specific Ab serum titers, high-avidity gp120-specific Ab titers,
and the frequency of GC B cells in the draining lymph nodes of immunized mice were measured. As expected, higher levels of gp120-specific
Abs were induced in IC-immunized mice compared with mice vaccinated with antigen alone (Fig. 3A). Mice immunized with the ICs
Lofano et al., Sci. Immunol. 3, eaat7796 (2018)
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from neutralizers demonstrated slightly higher levels of overall Ab
titers and more avid Abs compared with the mice vaccinated with
ICs from non-neutralizers (P < 0.05; Fig. 3, A and B). Furthermore,
higher frequencies of GC (CD19+CD30−CD95+) B cells were observed
after immunization with ICs from neutralizers compared with mice
immunized with ICs from non-neutralizers (Fig. 3C). Given the overlap in mouse and human FcR responses to human monoclonal Abs
(mAbs) (37), suggesting sufficient cross-species interaction, these data
suggest that the Fc differences in neutralizer Abs may not only represent a biomarker of a more effective humoral immune response
but also contribute to differences in GC activity.
Unique antigen-specific Ab glycosylation and elevated
immunoglobulin G1 are enriched among neutralizers
To define the biophysical differences in neutralizer and non-
neutralizer IC profiles that may have contributed to enhanced
3 of 12
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humoral immune responses, we interrogated differences in both immunoglobulin G (IgG) subclass selection levels and Fc glycosylation
profiles on HIV-specific Abs by capillary electrophoresis. Although
no differences were observed in antigen-specific IgG2, IgG3, and IgG4
levels across the two groups, neutralizers had higher HIV-specific
IgG1 titers to all HIV antigens, but not to influenza hemagglutinin (HA)
(Fig. 4, A and B, and fig. S2A), highlighting the infection-specific
change in Ab levels. Elevated HIV-specific IgG responses were not
linked directly to viral load, days after diagnosis, or viremic or elite controller status, but did negatively correlate with CD4 count (fig. S3, A
to D) (14, 37, 38). However, as previously reported, a trend was
observed in neutralization breadth and CD4 counts and viral load
(fig. S3, E and F) (12, 14, 38). Thus, differences in IC activity may be
attributable to higher overall HIV-specific IgG1 levels, which could
account for improved overall FcR binding. However, selectively
enhanced binding to C1q and FcRII (Fig. 2C) and immunization
differences using matched Ab-bound complexes (Fig. 3) could
not be explained by elevated IgG1 levels or differential subclass
selection profiles.
Given the emerging appreciation for the role of antigen-specific Ab
glycoforms in shaping Fc activity (28, 29), we profiled HIV-specific
Ab glycosylation (39). Using standard capillary electrophoresis (39)
on equivalent amounts of enzymatically collected Fc glycans from
neutralizers and non-neutralizers, we observed elevated levels of
sialylated glycan structures on HIV envelope–specific IgG-Fcs from neutralizers compared with non-neutralizers. In contrast, non-neutralizers
had higher levels of singly galactosylated (G1) structures on their
HIV-specific IgG1 Abs (Fig. 4, C and D). Thus, selective differences
in sialylation and galactosylation were observed among neutralizers
and non-neutralizers, pointing to qualitative differences in IgG1 Ab
after translational modifications.
To further define the minimal HIV-specific features that were
selectively enriched among neutralizers, we used an orthogonal multivariate partial least square discriminant analysis PLS-DA combining
all gp120-specific features. Using all Fc profile features, we observed
nearly complete separation between neutralizers and non-neutralizers
Lofano et al., Sci. Immunol. 3, eaat7796 (2018)
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HIV Ab glycoforms modulate IC-driven innate
and adaptive immunity
To define the involvement of sialylated Abs in driving affinity maturation and to separate the role of sialylation from Ab titer differences
between neutralizers and non-neutralizers (fig. S1A), we immunized
animals with ICs generated with a single mAb, but with differential
glycosylation. ICs were generated with an HIV-specific mAb (PGT121)
that was fractionated and enzymatically prepared into three separate Ab Fc fractions to generate agalactosylated ICs (G0-ICs), nonsialylated galactosylated ICs (G1/G2 NS-ICs), or sialylated ICs (G1/G2
S-ICs). Despite the presence of a glycan in the PGT121 Fab (40),
removal of sialylation did not affect PGT121 binding or affinity (fig.
S4, A to D). Mice were immunized with alum-formulated ICs, alum-
formulated antigen alone, or alum alone, and Ab levels, avidity, and
B cell frequencies were interrogated 10 days after the second immunization. Mice immunized with S-ICs exhibited increased gp120-
specific IgG titers compared with those immunized with NS-ICs,
G0-ICs, or gp120 alone (Fig. 5A). Moreover, immunization with
S-ICs also induced more avid gp120-specific Abs compared with all
other immunized groups (Fig. 5A). Although the Fab domain may
also be sialylated (41), such as in PGT121 (40), only the Fc glycan
contributes to FcR/complement interactions in an indirect manner
by reshaping the Ab Fc to tune FcR/complement engagement (42).
These data implicate Fc sialylation as a direct modulator of the
humoral immune response, rather than a simple biomarker of an
affinity-matured response.
Sialylated ICs drive enhanced antigen deposition
To begin to dissect the mechanism by which S-ICs contribute to enhanced B cell affinity maturation, we examined the distribution of
these ICs early after immunization. A number of cells have been implicated in IC capture and transfer to GCs, including sinusoidal macrophages (SSMs) and noncognate B cells that collectively transfer ICs
to FDCs. Glycan-fractionated PGT121-ICs were prepared with a fluorescently labeled gp120. The ICs were delivered intravenously, and
IC capture was measured by flow cytometry and immunofluorescent
microscopy 1 and 3 hours after IC administration. After 1 hour, significantly higher frequencies of ICs were observed on B cells and FDCs
in the presence of S-ICs compared with NS-ICs or antigen alone
(Fig. 5B); after 3 hours, SSMs, B cells, and FDCs captured higher
levels of ICs in the presence of sialylated Abs.
To visualize the localization of the ICs after delivery, we performed fluorescence microscopy on splenic follicles. One hour after
vaccination, follicles from mice receiving the sialylated ICs exhibited
greater IC deposition within the follicle than those receiving the nonsialylated ICs (Fig. 5C). Moreover, S-IC deposition was proximal to
4 of 12
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Fig. 3. Neutralizer ICs drive higher-avidity Abs and expanded GC B cell responses. (A to C) BALB/c mice were immunized twice, 3 weeks apart, with alum-
adjuvanted gp120 ICs (ICs-alum) generated with serum Abs from four neutralizers
(N) or four non-neutralizers (NN) (n = 5 to 8 mice per group, two experiments).
Control groups received alum-adjuvanted gp120 or adjuvant alone. Ten days after
the last immunization, we measured the titers of gp120-specific IgG Abs (A), the
titers of high-avidity gp120-specific IgG Abs (B) in sera, and the percentage of GC
B cells (C), defined as live CD3−CD19+CD38−CD95+ cells, in draining lymph nodes of
immune mice. All assays were run in duplicate, and a Mann-Whitney test was used to
compare responses induced by neutralizer (N) or non-neutralizer (NN) immunized
animals. *P < 0.05 and **P < 0.01. The horizontal bars in all panels indicate mean,
and error bars in all panels represent SEM.

(Fig. 4E). The dominant features that selectively split the two groups
included the level of sialylated glycan structures and overall levels of
gp120-specific IgG1 Abs, with the percentage of sialylated gp120-
specific Abs ranking as the top distinguishing feature (Fig. 4, E and F).
Consistent with previous studies pointing to an association between
the levels of vaccine-induced sialylated Abs and Ab affinity maturation (32), sialylated HIV-specific Abs were selectively enriched among
neutralizers, pointing to a potential link between posttranslational
Ab sialylation and affinity maturation across disease and vaccination.
However, whether sialylation represents a biomarker of a more highly
affinity-matured immune response or directly contributes to affinity
maturation remains unknown.
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FDCs, whereas NS-IC deposition, though infrequent, was observed
closer to SSMs. Furthermore, vaccination with the sialylated ICs induced higher numbers of gp120+ FDC areas per follicle, two on
average, and of larger size of the areas, compared with vaccination with nonsialylated ICs (Fig. 5D). Furthermore, after 3 hours,
greater antigen deposition was observed in the presence of S-ICs
compared with NS-ICs, colocalizing with GL-7+ GC B cells (Fig. 5E).
These data suggest that S-ICs may contribute to enhanced humoral
immune activity via the rapid and effective deposition of ICs within
GCs via enhanced IC capture and delivery to the follicle. How
sialylated ICs are selectively captured and delivered to the follicle
remains unknown.
Lofano et al., Sci. Immunol. 3, eaat7796 (2018)

17 August 2018

Sialylated Fc antigen effects are complement-dependent
Emerging data suggest that complement has an essential role in
IC-mediated antigen deposition on FDCs (17). We assessed whether
uptake of sialylated ICs depended on complement. Using a noncognate
reporter B cell line, Raji cells, expressing both complement and FcRs
(43–45), we assessed the capture of S-ICs and NS-ICs in the presence or absence of complement and/or FcRIIB blockade by flow cytometry. As expected, at the highest concentration, both S- and NS-ICs
were trapped by the noncognate B cells in the presence of complement;
however, S-ICs bound at higher levels in the presence of complement
compared with NS-ICs. In contrast, no difference was observed between S- and NS-ICs in the setting of FcRIIB blockade (Fig. 5F).
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Fig. 5. Sialylated Ab-ICs promote enhanced humoral immune responses. (A) The dot plots show gp120-specific Ab titers (left) or avid Ab titers (right) 10 days after the
second immunization in BALB/c mice receiving alum alone (green), alum-adjuvanted gp120 (blue), agalactosylated PGT121 (G0-ICs) with alum (aqua), nonsialylated galactosylated PGT121 (G1/G2 NS-ICs) with alum (lavender), or sialylated galactosylated PGT121 (G1/G2 S-ICs) with alum (pink) (n = 3 to 8 mice, two experiments). (B) The dot
plots highlight the number of fluorescently labeled ICs on noncognate B cells (gp120+ B cells), macrophages (gp120+ SSM), or FDCs (gp120+ FDCs) from draining lymph
node at 1 and 3 hours after injection with nonsialylated IC (NS-IC) or sialylated IC (S-IC) (n = 4 to 8 mice, two experiments). (C) The confocal microscopy images depict the
level of IC deposition in a B cell follicle 1 hour after a mouse is immunized with NS-ICs (left) or S-ICs (right) and stained for g120 (blue), macrophages (green), and GL-7
(red). Representative image of three images from two to three mice per condition. (D) The bar graphs show the number (left) and area occupied (right) of gp120+bead+
FDCs in a draining lymph node. (E) The confocal microscopy images depict IC deposition in a B cell follicle 3 hours after immunization and stained with the same targets
as (C). Representative image of three images from two to three mice per condition. (F and G) The line graphs demonstrate the percentage of bound Raji or naïve human
B cells after incubation with APC bead–labeled NS-ICs (yellow) or S-ICs (pink), with (colored line) or without complement (gray line), with (blue) or without complement
(light blue) alone, or -FcRIIB blocking Abs (hatched lines) (F, n = 2; G, n =3). (H) The dot plots show the gp120-specific IgG Ab titers (left) and high-avidity gp120-specific
Ab titers (right) after immunizing WT or C1q−/− C57BL/6 mice (n = 2 to 8, two experiments) with alum (white), gp120-alum (blue), NS-ICs with alum (yellow), or S-ICs with
alum (pink). (I) The dot plot highlights the ratio of high-avidity gp120-specific Abs to total gp120-specific Abs in WT (dark pink) versus C1q−/− (light pink) mice after immunization with S-ICs. All ELISAs were performed in triplicate, and a one-way ANOVA followed by Tukey’s post test was used for (A), (B), and (D). Mann-Whitney and one-way
ANOVA with Holm-Sidak’s multiple comparisons test were used for (H). Two-way ANOVA with Dunnett’s correction comparing samples with the negative control (no Ab,
no complement) was used for (G). Mann-Whitney test was used in (I). *P < 0.05, **P < 0.01, and ***P < 0.001. The horizontal bars in all panels indicate mean. Error bars
represent SEM in (B), (D), (H), and (I) and SD in (A).
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DISCUSSION

Although efforts in vaccine design to induce bNAbs continue to
struggle to drive broad tier 2 heterologous immunity, our evolving
appreciation for the unique immunological features of the broad
cross-tier neutralizing breadth that emerges naturally in a select
population of infected individuals provides unexpected insights for
the rational development of a protective vaccine. Here, we observed
that individuals who developed bNAbs had HIV-specific Abs with
enhanced CR and FcR binding, selectively skewed to induce phagocytosis and complement deposition via enhanced HIV-specific Ab
Fc domain sialylation. Given the importance of Fc binding for antigen
deposition in the GC and our emerging appreciation for enhanced
and persistent GC activation among individuals with neutralizing
Abs (10, 12, 15, 46), we speculated that the enhanced Fc functionality
could actively contribute to the evolution of HIV-specific neutralization breadth. ICs generated with either Abs from individuals with
these enhanced Fc functions or highly sialylated mAbs induced higher
titers of more avidly binding Abs after IC immunization. Thus, these
data suggest that the Fc domain of the Ab may modulate the formation of the GC reaction, catalyzing the persistent selection and affinity
maturation of B cells required to drive the unusual B cell selection
associated with the development of bNAbs against HIV.
Rational vaccine design has led to the creation of both stabilized
trimers and minimal scaffolds able to focus the immune response to
sites of neutralization vulnerability (8, 47, 48). However, vaccination
with these constructs continue to induce Abs with narrow breadth,
likely due to a limited amount of affinity maturation. This has led
the field to explore novel immunization strategies and alternate adjuvants, as well as to focus vaccine design on eliciting bNAbs in the
absence of high levels of somatic hypermutation (6, 49, 50). Our results suggest that naturally modified Abs can selectively augment
affinity maturation via the rapid capture and delivery of antigens to
the GC. These data are consistent with studies of influenza vaccination, where the level of HA-specific Ab sialylation was associated with
the extent of affinity maturation (32). In our study, the administration
Lofano et al., Sci. Immunol. 3, eaat7796 (2018)
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of selectively glycosylated Abs at the time of antigen exposure led to a
marked increase in antigen deposition and maturation of high-avidity
Abs, pointing to a role for antigen-specific Ab glycosylation as a regulator of GC activity. Whereas Fab glycosylation is more uniform (41)
and not involved in Fc/FcR interactions (42), mounting data suggest
that Ab Fc glycosylation is programmed in an antigen-specific manner (51), modulated by vaccination (51, 52), and tuned by adjuvants
(53), which offers an opportunity for manipulating the quality of innate immune–recruiting Abs to enhance immunity upon boosting.
Beyond the role of immune activation, low CD4 T cell counts,
and high viral loads as drivers of neutralizing Ab breadth, recent
data suggest that individuals who generate bNAbs have autoimmune-
like transcriptional signatures (54–56). These transcriptional programs may enable B cells to break the necessary tolerance to evolve
polyreactive B cell receptors and drive extensive affinity maturation
(5, 56, 57), even within framework regions that are rarely targeted
for somatic mutation in healthy B cells (10). Similarly, IC levels and
signaling have been linked to autoimmune signatures in B cells in
individuals with rheumatoid arthritis and lupus (58–60). However,
whether neutralizers have autoimmune-like signatures due to intrinsic
differences in their B cell populations or due to the higher abundance
of ICs that can interact with FcRs and CRs is unknown. Nevertheless,
it is plausible that increased IC signaling could lead not only to enhanced antigen deposition but also to increased B cell activation, enabling antigen-specific B cells to undergo more extensive maturation,
tolerate more mutations, and even develop responses to cross-reactive
epitopes. Thus, linked to emerging rationally designed antigens, immunization strategies that also selectively direct the Fc domain of the
induced humoral immune response may stimulate the needed maturation to induce protective immunity.
Complement has a vital role in IC delivery to FDCs (17, 19, 20);
however, the specific Ab modifications that enable more effective
IC capture within GCs has been less clear. A number of different
cells contribute to the delivery of ICs to the GC including naïve noncognate B cells and macrophages, which typically acquire ICs via
different combinations of FcRs and CRs (35, 61, 62). Previous associations between sialylated HA-specific Abs and affinity maturation
(32) suggested that enhanced IC deposition was linked to IC signaling
via CD23 (FcRII), which is highly expressed on B cells. Although
CD23 may have a role in affinity maturation (63), the data presented
here build on our previous understanding of the critical role of complement in IC capture and deposition on FDCs and provide evidence
for a mechanistic involvement of sialylation in the acceleration of
antigen deposition and B cell maturation. Whether the deposited ICs
accelerate affinity maturation by providing more antigen to drive
higher frequencies of B cells that must compete more aggressively
for limited T cell help or lead to tighter binding ICs that require B
cell receptors to capture antigen more “avidly” for survival signals is
unclear. It remains unknown whether the antigen specificity of the
ICs influences this effect. Data from our longitudinal samples indicate that Fc interactions are higher in patients that develop neutralizing Abs even before neutralizing Abs have developed, suggesting that
non-neutralizing Abs could contribute to this effect. Future studies
focusing on human Abs in human Fc chimeric mice, in the presence of
other mAb specificities, including those that are non-neutralizing,
linked to sophisticated affinity maturation measures, may elucidate
the mechanisms underlying the adjuvanting effects of the IC-Fc. Nonetheless, the data here highlight the “adjuvanting” activity of sialylated
Abs in B cell maturation, pointing to potential opportunities to leverage
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Increased binding of S-ICs compared with NS-ICs, in the presence of
complement, was confirmed on naïve primary human B cells (Fig. 5G).
These data suggest a dominant role for S-IC interaction with complement in IC capture.
To confirm the interaction between S-ICs and complement, we
performed IC-based immunizations in complement-deficient mice.
Wild-type (WT) or C1q-deficient (C1q−/−) congenic mice were immunized twice with the ICs or antigen alone. As expected, antigen-
specific Ab responses were highest in the WT mice immunized with
S-ICs, with intermediate levels observed in WT mice vaccinated with
NS-ICs or antigen alone (Fig. 5H). However, a significant reduction
in Ab titers and avidity were observed in the C1q−/− mice vaccinated
with S-ICs compared with WT mice (Fig. 5H). Moreover, whereas
all animals appeared to reach a plateau after the second boost, the
C1q−/− mice immunized with S-ICs exhibited lower Ab titers and
avidity compared with WT counterparts (Fig. 5, H and I). These
data provide further evidence to support a role in Ab sialylation in
complement-dependent IC delivery for B cell priming and boosting. Although these data do not preclude a role for other FcRs in
IC-mediated antigen deposition in the lymph node, they support a
critical role for sialylated Ab-induced complement deposition as a
driver of high-affinity B cell responses.
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MATERIALS AND METHODS

Study design
The goals of this study were to identify unique properties of the Abs
from individuals with bNAbs to HIV and to determine whether these
properties could affect the humoral immune response. We used
systems serology, computational analysis, enzyme-linked immunosorbent assay (ELISA), glycan analysis, Luminex, flow cytometry,
confocal microscopy, and mouse immunization to accomplish these
goals. The samples were blinded throughout the initial Fc profiling
and unblinded for analysis. The number of independent experiments
and inclusion of individuals is described in the figure legends and in
Materials and Methods.
Study individuals
A total of 131 controllers were included for cross-sectional studies,
including both elite controllers, who spontaneously control viral
replication to undetectable levels (<75 copies/ml; CD4, 353 to 1813
cells/mm3), and viremic controllers with detectable but low viral loads
(~20 to 1658 copies of RNA/ml; CD4, 172 to 1794 cells/mm3) (15).
Days after diagnosis of HIV range from 1 to 30 years, with similar distributions across neutralizers and non-neutralizers. All individuals signed informed consent, and the study was approved by the
Massachusetts General Hospital (MGH) Institutional Review Board.
HIV-1 neutralization breadth was assessed using the TZM-bL cell–based
pseudovirus neutralization assay (65) against a panel of Env pseudoviruses derived from nine clade B tier 2 (AC10.0.29, RHPA4259.7,
THRO4156.18, REJO4541.67, WITO4160.33, TRO.11, SC422661.8,
QH0692.42, and CAAN5342.A2) and two tier 3 (PVO.4 and TRJO4551.58)
neutralization sensitivities. Neutralization was defined as at least 50%
inhibition of infection at a 1:20 dilution. The neutralization breadth was
defined as the percentage of the 11 isolates neutralized by each plasma
sample; neutralizers were able to neutralize anywhere from 1 virus
(9% breadth) to all 11 viruses (100% breadth), and non-neutralizers
had undetectable cross-neutralization against all 11 tier 2/3 viruses.
All samples that showed reactivity to the murine leukemia virus–
pseudotyped virion controls were excluded.
In addition, longitudinal plasma samples were included from
26 acutely infected individuals who were recruited as part of the
San Diego Acute and Early Infectious Disease Research Program (7).
Twelve individuals developed neutralizing Ab breadth after 2 to
3 years of infection, whereas 14 individuals (matched for age, gender,
Lofano et al., Sci. Immunol. 3, eaat7796 (2018)
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and ethnicity) did not develop any appreciable tier 2 neutralizing Ab
breadth. Plasma samples were analyzed at 1 month, 6 months, and
1 year after the estimated time of infection. These limited time points
were included not only to ensure that sampling occurred before the
evolution of neutralizing Ab breadth but also to maintain consist
ency in comparison for matched durations of infection. All individuals provided informed consent at their respective institutions.
Functional assays
ADCP assay
The THP-1 phagocytosis assay was performed as previously described
(66). Briefly, THP-1 cells were purchased from the American Type Culture Collection and cultured as recommended. Biotinylated rgp120-YU2
(Immune Technology) was used to saturate the binding sites on 1-m
fluorescent neutravidin beads (Invitrogen) overnight at 4°C. Excess
antigen was removed by washing, and then beads were incubated with
patient Ab samples for 2 hours at 37°C. After opsonization, THP-1 cells
were added and incubated overnight to allow phagocytosis. Cells were
then fixed with 4% paraformaldehyde (PFA), and the extent of phagocytosis was measured via flow cytometry on a BD LSR II flow cyto
meter equipped with high-throughput sampler. The data are reported
as a phagocytic score, which takes into account the proportion of effector cells that phagocytosed and the degree of phagocytosis [integrated mean fluorescence intensity (MFI): frequency × MFI]. Each Ab
sample was tested over a range of concentrations (0.1 to 100 g/ml).
ADCC assay
The rapid fluorescent ADCC assay was performed as previously described (67). Briefly, CEM-NKr cells were pulsed with rgp120-YU2
proteins (6 g/ml) and labeled with the intracellular dye carboxyfluorescein diacetate succinimidyl ester (CFSE) and the membrane dye
PKH26. NK cells were enriched directly from seronegative donor
whole blood by negative selection using RosetteSep (STEMCELL
Technologies). Purified IgG was added to the labeled, antigen-
pulsed CEM-NKr cells before the addition of fresh NK cells. The cells
were incubated for 4 hours at 37°C and then fixed with 4% PFA.
The proportion of cells that maintained membrane expression of
PKH26 but lost CFSE staining (i.e., lysed cells) were quantified via
flow cytometry.
Ab-dependent complement deposition
ADCD was assessed by the measurement of complement component
C3b on the surface of target cells. CD4-expressing target cells were
pulsed with the rgp120-YU2 protein and incubated with serum Abs.
Freshly isolated HIV-negative donor plasma diluted into veronal buffer with 0.1% gelatin (1:10 dilution) and the cells were incubated for
20 min at 37°C. The cells then were washed with 15 mM EDTA in
phosphate-buffered saline (PBS), and complement deposition was detected via flow cytometry after staining for C3b (Cedarlane). Replicates
using heat-inactivated donor plasma were used as negative controls.
IC uptake by Raji B cells and primary human naïve B cells
Ab-dependent binding to CRs was assessed using CR-expressing
Raji cells (68) or naïve B cells from fresh peripheral blood mononuclear cells (PBMCs). Specifically, biotinylated avitag-gp120-YU2
(ImmuneTech) was combined with allophycocyanin (APC)–labeled
streptavidin (Invitrogen) for 2 hours at 37°C. Serial dilutions of
sialylated PGT121 or nonsialylated PGT121 Abs were added to prepare S-ICs or NS-ICs, respectively. ICs were washed with PBS + 5%
bovine serum albumin (BSA) and incubated with 5 × 104 Raji B cells
or 106 human PBMCs per well for 30 min at 37°C with or without freshly reconstituted guinea pig complement in the presence or absence
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the Fc domain to drive enhanced affinity maturation in the context
of HIV vaccination.
Complement-activating Abs have also been implicated in the destruction of HIV virions (64). Thus, sialylation may provide a bifunctional advantage in driving enhanced affinity maturation and
direct antiviral control of HIV. Although HIV can mutate rapidly to
escape the selection pressure from neutralizing Abs in the context of
natural infection, it is plausible that vaccines inducing complement-
depositing Abs against HIV may enhance both Fab- and Fc-mediated
control of the virus. Thus, with our emerging ability to directly program Ab glycosylation, via distinct immunogens (51) or adjuvants
(53), next-generation vaccine strategies may harness the full antiviral
breadth of the humoral immune response. Thus, coupled to sophisticated emerging immunogens, manipulation of the Fc domain of the
Ab may support the evolution of neutralizing Abs that block most
strains of HIV infection.
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neutral (G0F, G1F, G1FB, and G2F). Sialylated or galactosylated
glycoforms were not detected after neuraminidase or galactosidase
S treatment, respectively. Neuraminidase-treated nonsialylated PGT121
retained its ability to bind efficiently to gp120 by ELISA (fig. S3B) and
surface plasmon resonance (fig. S3C), as previously described (71).

Luminex subclass assay, FcR, and complement
protein binding
A custom Luminex assay was used to quantify the relative concentration of HIV-specific Ab subclass levels, as previously described (69).
Briefly, microplex carboxylated beads (Luminex) were coupled to the
indicated proteins via covalent N-hydroxysuccinimide (NHS)–ester
linkages by combining 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and NHS (Thermo Scientific) in PBS, as recommended by the
manufacturer (antigens: gp140-SF162, gp120-YU2, gp41- HXBc2,
p24-HXBc2, and HA-Brisbane/60/09). The coupled beads [50 l of a
solution (100 microspheres/l) in 0.1% BSA in PBS] were added to
each well of a 96-well filter plate (Millipore). The purified IgGs [50 l
of each sample diluted to IgG (200 g/ml)] were added to five wells
of the 96-well plate and incubated at 4°C overnight. The beads were
washed three times with 100 l of PBS–Tween 20, and individual
IgG isotype detection reagents (bulk IgG, IgG1, IgG2, IgG3, and IgG4)
conjugated to phycoerythrin (PE) (Southern Biotech) were added
individually to each of one of the five wells. The 96-well plate was
incubated with shaking for 2 hours, washed three times, and read on
a Bio-Plex 200 instrument. Similarly, FcRIIA, FcRIIB, FcRIIIA,
FcRIIIB, and C1q were biotinylated (Pierce 21331), conjugated to PE
(Southern Biotech), incubated with coupled beads and purified IgG,
and analyzed on a Bio-Plex 200 instrument to test the FcR and complement protein binding capacity of HIV-specific Abs, as previously
described (70).

IC preparation
To separate the effects of elevated Ab titers from adjuvanting effects of
unique Fc domains in the neutralizers, we selected polyclonal pools of
Abs across the neutralizers and non-neutralizers that had equivalent
titers and avidity. Specifically, gp120-specific binding titers and avidity
were assessed across the top 10 neutralizers and the bottom 10 neutralizers (fig. S1A). Although gp120-specific titers were higher among the
neutralizers, four individuals were selected from each group that had
equivalent gp120-specific titers and avidity (encircled in red). Binding
curves were performed to define the optimal concentration (1:30) of
plasma to achieve equivalent bead occupancy (fig. S1, B and C).
For the preparation of ICs, biotinylated avitag-gp120-YU2
(ImmuneTech) was combined with APC-labeled or unlabeled
streptavidin (Invitrogen) for 2 hours at 37°C. Polyclonal pools of
neutralizer/non-neutralizer Abs were added at a ratio of 1:30. For mAb
experiments, G0-PGT121, S-PGT121, or NS-PGT121 Abs were added
at a ratio of 1:2 antigen/Ab and incubated for 2 hours at 37°C. All
ICs were then incubated with 2:1 (antigen + Ab)/alum for 30 min at
room temperature and finally brought to a final volume of 100 l
per mouse with PBS. ICs were tested for endotoxin before immunization using a Limulus Amebocyte Lysate test (Thermo Fisher) according to the manufacturer’s instructions and were found to have
comparable low/undetectable levels of endotoxin in each sample.

Glycan analysis
The relative abundance of Ab glycan structures was quantified by
capillary electrophoresis, as previously described (39). Briefly, antigen-
specific Abs were purified using gp120-coupled magnetic beads (New
England Biolabs) and then treated with IdeZ protease (New England
Biolabs) to collect the Ab Fc portion. N-glycans were removed from
the Fc domains and labeled with 8-aminopyrene-1,3,6-trisulfonic acid
(APTS) using the GlycanAssure APTS Kit (Thermo Fisher), as described in the manufacturer’s protocol. Labeled glycans were loaded
onto the 3500 Genetic Analyzer (Thermo Fisher). Peaks of five major
glycan structures (G0, G1, G2, bisecting, and sialylated) were identified. The relative abundance of each glycan structure was determined
by calculating the area under the curve, normalized for equal amounts
of loaded APTS dye, of each peak divided by the total area of all peaks.
Purification of Ab glycoforms and ICs
PGT121 mAb was used to generate agalactosylated, galactosylated
nonsialylated, and galactosylated sialylated Abs and then formulated
with gp120 to prepare G0-ICs, NS-ICs, and S-ICs, respectively.
Sialylated PGT121 mAb was used to generate Ïnonsialylated and agalactosylated Abs. The Ab was incubated overnight at 37°C with neura
minidase (Millipore Sigma) or galactosidase S (New England Biolabs)
to generate nonsialylated or agalactosylated Abs, respectively. Glycoprofiles of the modified mAbs were confirmed by glycan sequencing
(fig. S3A) and by Western blot using Sambucus nigra agglutinin
(SNA)–biotin that binds to sialic acid. Fc glycoform composition without neuraminidase treatment was 13.14% sialylated (G2S1F) and 86.86%
Lofano et al., Sci. Immunol. 3, eaat7796 (2018)
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Mice and vaccinations
Pathogen-free BALB/c female mice (the Jackson Laboratory) aged
6 weeks were used in this study. All animal studies were carried out in
compliance with current regulations of the MGH Center for Comparative Medicine at the Ragon Institute animal facility. To measure
the frequencies of gp120+ immune cells by flow cytometry and to
detect the B cell follicles by confocal microscopy, mice received one
intravenous vaccination with fluorescently labeled ICs in PBS. To
measure the gp120-specific Ab and B cell responses, mice received
two intramuscular vaccinations with alum-adjuvanted ICs 3 weeks
apart, and then analysis was performed 10 days after the last immunization. All formulations were adjusted with PBS to bring up to
100 l per mouse. C1q−/− (72) and WT mice in a C57BL/6 background were used to assess the role of the C1q complement protein
after vaccination; these mouse experiments were approved and performed according to the guidelines of the Washington University
School of Medicine Animal Safety Committee.
Flow cytometry
For the characterization of the innate and the GC B cell responses,
cell suspensions prepared from spleen, or pairs of draining inguinal
lymph nodes from each mouse, were stained with blue live/dead
cell stain (Invitrogen) for 20 min at room temperature and then incubated with Fc block (BD Biosciences) in PBS plus 1% fetal bovine
serum (HyClone, Thermo Scientific) for 10 min at 4°C. About 107
splenocytes or 2 × 106 to 3 × 106 lymph node cells were stained for
30 min at 4°C with the following mAbs: anti-CD19 APC-H7 (BD
Biosciences), anti-CD3 BV785 (BioLegend), anti-CD38 peridininchlorophyll-protein complex (PerCP)–C5.5 (BD Biosciences), and
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of anti-FcRII Ab. Cells were stained with a viability dye (eBioscience),
and Abs against CD3, CD14, and CD19, and then fixed with 100 l
of 4% PFA before flow cytometry analysis. The percentage of bead+
Raji B cells or live+CD3−CD14−CD19+ cells were enumerated across
different conditions.
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anti-CD95 BV510 (BD Horizon). Cells were analyzed on a FACS Fortessa
(BD Biosciences), and data analyses were performed using FlowJo
software v9.6 (Tree Star).

Confocal microscopy
Spleens were collected from immunized animals at the appropriate
time points and cut into ~5-mm-thick pieces, immediately submerged
in optimal cutting temperature (O.C.T.) compound (Tissue-Tek, Sakura),
snap-frozen using 2-methylbutane (isobutene) and liquid nitrogen,
and stored in liquid nitrogen until processing. The cryosections (40 m
thick) were cut along the entire organ to analyze all planes. The cryosections were fixed using ice-cold acetone for 10 min at room temperature and rehydrated in PBS for 5 min. Sections were then blocked
by Background Sniper (Biocare) and stained using anti-CD35 (IgG-
purified, BD Pharmingen) or anti–GL-7 (IgM-purified, eBioscience),
followed by rat anti-IgG Alexa568 (Abcam) or by rat anti-IgM Texas
Red (Sigma), respectively. Sections were also stained with anti-CD169
[fluorescein isothiocyanate (FITC), BioLegend]. The antigen APC-
labeled gp120 used for the immunizations was detected. After washing three times with PBS, stained tissue sections were sealed using
Gold Antifade reagent (Invitrogen–Life Technologies) and a coverslip.
Images were acquired with a Zeiss LSM 510 confocal microscope.
Statistical analysis
PLS-DA defined the relationship between the input as a linear combination of all features among neutralizers or non-neutralizers (33).
PLS-DA seeks the latent variables, which linearly combine all features, that explain the maximum variance between the groups; this
approach generates a model with the greatest separation among groups
with the lowest possible mean squared error. Before PLS-DA, the data
were normalized with mean centering and variance scaling; 10-fold
cross-validation was performed by iterative random exclusion of subsets of sample data (in groups of 10%) during model calibration, and
then the excluded data were used to test model predictions. Ultimately,
each variable identified in the model was weighted for its contribution
to splitting the groups, aimed at generating a variable importance in
projection.
Analysis of variance (ANOVA), followed by Tukey’s, Dunnett’s,
or Bonferroni’s post tests, was performed using GraphPad Prism
7 software (GraphPad Software) to compare differences between more
than two groups. A Spearman correlation, followed by Bonferroni
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Sweetening up antibodies
Certain individuals (neutralizers) infected with HIV are able to generate broadly neutralizing antibodies more
efficiently than others (non-neutralizers). By comparing HIV-specific antibodies isolated from neutralizers and
non-neutralizers, Lofano et al. found sialylation of the Fc domain to be higher in neutralizers. To understand the biological
functions of Fc domain sialylation, the authors generated sialylated and nonsialylated isoforms of an HIV gp120-specific
antibody, PGT121. By generating immune complexes of sialylated or nonsialylated PGT121 bound to fluorescently
labeled HIV gp120, they found that sialylation enhanced the deposition of antigen in B cell follicles in a
complement-dependent manner. Besides stressing the importance of the Fc domain in regulating antibody functions, the
study also highlights the role of the complement pathway in driving humoral immunity.

